ACIP Expands Recommendation on PCV13 to Include Certain High-risk Kids, Teens

The CDC's Advisory Committee on Immunization Practices (ACIP) voted to expand the age recommendation for administration of the 13-valent pneumococcal conjugate vaccine (PCV13) to certain individuals during its Feb. 20-21 meeting in Atlanta. Committee members also discussed and voted on a number of other vaccine-related issues of interest to family physicians. According to Jamie Loehr, M.D., of Ithaca, N.Y., the AAFP's liaison to the ACIP, the committee voted unanimously to provisionally recommend that PCV13, which is marketed by Pfizer Inc. as Prevnar 13, routinely be given to immunocompromised, PCV13-naive children and adolescents ages 6 to18 years.
Source: AAFP Health of the Public - Category: Primary Care Source Type: news